BioSpace News Archive

Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib).

Designing solutions for medical device OEMs is the expertise of Moldworx LLC, a Gilbert, Arizona-based custom designer and builder of molds, automation solutions, and custom molding

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, with a proprietary drug device combination product for the magnetic resonance imaging (MRI) market, announces that it has issued 705,040 new ordinary shares of £0.00037 each in the capital of the Company (“Ordinary Shares”) at exercise price of 15 pence per share

The United States currently spends upwards of $420 million per hour on healthcare, a number that is increasing by the minute, and if current trends continue, the nation’s total healthcare spending will top $12 trillion in 2040, according to HealthCostCrisis.org, a new, interactive website and crisis clock that tracks and forecasts healthcare spending in America in real time.

Agilent Technologies Inc. (NYSE: A) announced today the shipping of a new instrument that offers laboratories a more affordable, low-throughput option for analyzing the quality of RNA and DNA samples.

Forbes announced that Westlake Village BioPartners founding managing director Beth Seidenberg, MD, has been ranked 59 on the annual Midas List of the world’s top 100 technology venture capitalists.

Personalis a leader in advanced genomics for cancer, today announced the appointment of Aaron Tachibana as Chief Financial Officer.

Flatiron Health today announced that Black Book Research, an industry-leading source for polling, surveys and market research found that Flatiron’s oncology technology, including its electronic health record (EHR) and practice management solutions, outperform all other offerings in eight total categories, ranking #1 overall for end-to-end oncology technology.

Clinical stage biotechnology company Que Oncology today announces the launch of its Phase II trials which will see its novel non-hormonal therapy, for women with breast cancer suffering hot flashes and night sweats, tested at key sites in the United States.

Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, announced today that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).